Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GLS | O94925 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27694614 | 0.89 | PTGS2 (0.53) | CYP2C19GLSPOLBCYP1A2PKM | |
| SCHEMBL27814116 | 0.87 | CYP2C19 (0.41) | CYP2C19GLSHPGDTSHRKMT2A | |
| SCHEMBL2016201 | 0.85 | HPGD (0.49) | CYP2C19HPGDTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL819824 | 0.85 | GLS (0.46) | CYP2C19GLSHPGDTSHRKMT2A | |
| SCHEMBL29211037 | 0.85 | ESR1 (0.51) | CYP2C19CYP2D6SRCCHRM1POLB | |
| SCHEMBL819828 | 0.85 | KMT2A (0.58) | GLSHPGDTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL6802549 | 0.85 | EPHX1 (0.58) | CYP2C19GLSHPGDTSHRKMT2A | |
| SCHEMBL25201694 | 0.83 | L3MBTL1 (0.42) | CYP2C19HPGDKMT2ACYP2D6POLB | |
| SCHEMBL14232829 | 0.83 | GLS (0.45) | CYP2C19GLSHPGDTSHRKMT2A | |
| SCHEMBL30387958 | 0.83 | L3MBTL1 (0.42) | CYP2C19HPGDKMT2ACYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| EP-3383873-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-108349966-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-109678685-B | Preparation method of 1-indanone and derivatives thereof | 中南民族大学 | 2021-11-05 | — | — | CN | disclosed |
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | disclosed |
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107074887-B | Substituted dihydropyrrolopyrazoles | 宇部兴产株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
| US-6080587-A | RATIONALLY DESIGNED LIBRARIES OF STRUCTURALLY-DIVERSE LOW MOLECULAR WEIGHT COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0906265-A1 | CHEMICAL PROCESS | ZENECA LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048671-A1 | CHEMICAL PROCESS | ZENECA LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5693720-A | COMPOUND HAVING ORGANIC NON-PEPTIDE MOIETY LINKED TO SOLID SUPPORT THROUGH SULFIDE; PHOTOSENSITIVITY | ELI LILLY AND COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0712493-A4 | A METHOD FOR PREPARING AND SELECTING PHARMACEUTICALLY USEFUL NON-PEPTIDE COMPOUNDS FROM A STRUCTURALLY DIVERSE UNIVERSAL LIBRARY | SPHINX PHARMA CORP (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0712493-A1 | A METHOD FOR PREPARING AND SELECTING PHARMACEUTICALLY USEFUL NON-PEPTIDE COMPOUNDS FROM A STRUCTURALLY DIVERSE UNIVERSAL LIBRARY | SPHINX PHARMACEUTICALS CORPORATION (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5502246-A | Solid-phase synthesis utilizing photochemical carbon-sulfur bond cleavage of thioethers | ELI LILLY AND COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995004277-A1 | A METHOD FOR PREPARING AND SELECTING PHARMACEUTICALLY USEFUL NON-PEPTIDE COMPOUNDS FROM A STRUCTURALLY DIVERSE UNIVERSAL LIBRARY | SPHINX PHARMACEUTICALS CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981904-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | CYP2C19 487/4885GLS 2/4885HPGD 389/4885 |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | GLS2, GLS, GLUL | CYP2C19 487/4885GLS 2/4885HPGD 389/4885 |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | CYP2C19 487/4885GLS 2/4885HPGD 389/4885 |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | BAD, BAK1, BRDT | CYP2C19 3590/4885GLS 134/4885HPGD 917/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | CYP2C19 158/4885GLS 207/4885HPGD 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.